Literature DB >> 28053714

Respiratory muscle training may improve respiratory function and obstructive sleep apnoea in people with cervical spinal cord injury.

C L Boswell-Ruys1, C R H Lewis2, S C Gandevia1, J E Butler3.   

Abstract

STUDY
DESIGN: This is a double-blind crossover case study series.
OBJECTIVES: The objective of this study was to assess the feasibility of respiratory muscle training (RMT) as an effective intervention to improve lung function and obstructive sleep apnoea (OSA) in cervical spinal cord injury (SCI) patients.
SETTING: This study was conducted in Australia.
METHODS: Three adults (C5-6, AIS A-C) participated in this study. They trained with an RMT device (active or sham) for 4 weeks followed by 2 weeks of rest, and then trained with the alternate device for 4 weeks. RMT occurred twice daily, 5 days a week, and it consisted of three sets of 12 inspirations and three sets of 12 expirations. Training intensity commenced at 30% maximal inspiratory pressure (MIP) and 30% maximal expiratory pressure (MEP), which was increased every second day by 10%. Spirometry, MIP, MEP, polysomnography and Epworth Sleepiness Scale (ESS) were measured before and after every 4 weeks of training.
RESULTS: After active RMT, vital capacity and inspiratory capacity improved from baseline in all participants (by 44%, 60% and 18% and by 18%, 46% and 5%, respectively); MIP improved by 40 and 17% from baseline in two subjects; and MEP improved in all participants. Two participants had OSA, and after active training their obstructive apnoea-hypopnoea index improved from 30 to 21events per hour and from 72 to 18 events per hour, and ESS marginally improved. Sham RMT resulted in minimal changes in all measures.
CONCLUSION: RMT is feasible and likely effective to increase respiratory muscle strength, to improve lung function, and to reduce the severity of OSA and sleepiness in people with cervical SCI. A randomised controlled trial is planned to validate these findings and to examine respiratory-related morbidity and quality of life.

Entities:  

Year:  2015        PMID: 28053714      PMCID: PMC5129389          DOI: 10.1038/scsandc.2015.10

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  4 in total

1.  Characteristics of sleep apnea syndrome in tetraplegic patients.

Authors:  E Stockhammer; A Tobon; F Michel; P Eser; W Scheuler; W Bauer; M Baumberger; W Müller; T H Kakebeeke; H Knecht; G A Zäch
Journal:  Spinal Cord       Date:  2002-06       Impact factor: 2.772

2.  Recent trends in mortality and causes of death among persons with spinal cord injury.

Authors:  M J DeVivo; J S Krause; D P Lammertse
Journal:  Arch Phys Med Rehabil       Date:  1999-11       Impact factor: 3.966

3.  Effects of oropharyngeal exercises on patients with moderate obstructive sleep apnea syndrome.

Authors:  Kátia C Guimarães; Luciano F Drager; Pedro R Genta; Bianca F Marcondes; Geraldo Lorenzi-Filho
Journal:  Am J Respir Crit Care Med       Date:  2009-02-20       Impact factor: 21.405

Review 4.  Mechanisms of apnea.

Authors:  Danny J Eckert; Atul Malhotra; Amy S Jordan
Journal:  Prog Cardiovasc Dis       Date:  2009 Jan-Feb       Impact factor: 8.194

  4 in total
  3 in total

1.  The effects of threshold inspiratory muscle training in patients with obstructive sleep apnea: a randomized experimental study.

Authors:  Huei-Chen Lin; Ling-Ling Chiang; Jun-Hui Ong; Kun-Ling Tsai; Ching-Hsia Hung; Cheng-Yu Lin
Journal:  Sleep Breath       Date:  2019-05-21       Impact factor: 2.816

Review 2.  A Review of Different Stimulation Methods for Functional Reconstruction and Comparison of Respiratory Function after Cervical Spinal Cord Injury.

Authors:  Jiaqi Chang; Dongkai Shen; Yixuan Wang; Na Wang; Ya Liang
Journal:  Appl Bionics Biomech       Date:  2020-09-17       Impact factor: 1.781

3.  Effectiveness of respiratory muscle training for patients with obstructive sleep apnea: A protocol of systematic review and meta-analysis.

Authors:  Shi-Min Xue; Juan Jia; Ping Fan; Shi-Wei He
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.